Prefilled Injectables, Once an Anomaly, Fast Becoming a Prerequisite for Competing in a Growing List of Healthcare Segments

(Nashua, NH) – Although barely ten years old, a number of market and technology factors have converged over the past five years to make the market for prefilled syringes and injectors the fastest growing segment in the drug delivery sector. The result is a drug delivery technology that has become an essential element of product development strategies for an increasing number therapeutic indications.

Prefilled devices owe their growth to several key forces. As the number of injectable drugs indicated for chronic conditions has increased, the compelling case for patient self-administration has led drug developers to increasingly seek to partner with device designers to create safe and effective ways to allow patients to self-inject their medications. The drive to enhance patient and caregiver safety and improve patient compliance with drug protocols has placed new emphasis on injection devices that protect users from accidental needlesticks and provide a more convenient and less complicated experience for the patient. And the economics of high-cost recombinant protein drugs has been a significant factor in the goal of replacing drug vials, which must be overfilled to account for drug loss during the syringe filling process, with cartridges and devices that can be filled on quality controlled automated fill-and-finish lines.

Among the important parenteral self-administration healthcare markets, diabetes and the family of autoimmune diseases continue to lead the push toward prefilled injection devices. Currently a dozen branded drugs approved for treating one or more autoimmune conditions are marketed as prefilled products. And in Europe more than three-quarters of Type 1 diabetics self-administer insulin in prefilled pen injectors. The majority of injectable GLP-1 analogs indicated for glycemic control in Type II diabetics are marketed in prefilled pens.

The trend is similar in other therapeutic segments. Eighty percent of hematopoietic drugs for anemia and neutropenia are marketed as prefilled combination products, as are branded injectables for treating infertility. Seven of the eight major brands of human growth hormone are available in pen injectors. And the majority of branded neurology drugs for treating migraine and schizophrenia are sold prefilled.

This trend toward prefilled injectable devices will continue unabated, as device designers and manufacturers continue to tweak and improve the delivery containers they offer. Chronic disease patients and their caregivers have become accustomed to the safety, efficiency and convenience of prefilled devices, making this packaging and delivery strategy an indispensable approach for market participants in the growing number of therapeutic markets where prefilled syringes, pens, autoinjectors, and needle-free injectors have established a presence.

These conclusions are taken from a recent survey conducted by Applied Data Analytics. The survey’s findings can be found in a new and comprehensive report. The Global Syringe & Injector Analysis and Assessment report contains highly detailed data and knowledge on device designs, combination products, supplier relationships, market share information and data forecasts in thirteen key therapeutic categories.

For more information, please visit:
http://applieddata.org/Pharmaceutical_Biotech_Industry_Reports.htm


Source: Applied Data Analytics

About Applied Data Analytics

Applied Data Analytics assists life science management decision makers by providing analysis services and products that can reveal key relationships, patterns and trends affecting their businesses. These information tools encourage opportunity and risk discovery by promoting comprehensive, timely, and insightful analysis, allowing managers to make informed tactical and strategic decisions.

Contact:

Greg Stone
Applied Data Analytics
98 Amherst Street
Amherst, NH 03031 USA
Voice: 603-718-4564
www.applieddata.org

This release was published on openPR.